Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 16, 2004. The report primarily details corporate actions regarding share buybacks, treasury holdings, and changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, or debt levels. Specific financial data points disclosed include:
- Share Repurchase Price: 1,205.2011 pence per share.
- Treasury Shares Held: 53,228,000 shares (post-repurchase).
- Shares in Issue: 5,883,297,696 shares (excluding Treasury shares).
- Dividend Reinvestment Price: Corrected to £12.07 per share.
Material Changes
The primary material change reported is the execution of a share buyback program authorized by shareholders at the Annual General Meeting on May 17, 2004. On November 15, 2004, the company purchased 500,000 Ordinary shares to be held in Treasury. Additionally, a correction was issued regarding Director John Coombe's share interest, adjusting the increase from 126 shares to 125 shares due to a revised dividend reinvestment price.
Outlook, Risks, and Management Commentary
The filing contains no management commentary on future business outlook, strategic risks, or contingencies. It strictly reports on the mechanics of the share repurchase and employee trust transactions. The company explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 500,000 share repurchase at the stated price of 1,205.2011 pence.
- Confirm the updated total number of shares in issue (5,883,297,696) and treasury holdings (53,228,000).
- Note the correction in Director John Coombe's holdings due to the dividend reinvestment price adjustment.
- Review the authority granted at the May 17, 2004 AGM to ensure the buyback volume remains within approved limits.